Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 4/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | CHUK | O15111 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9770996 | 0.92 | CKS1B (0.38) | TOP2ACKS1BSKP2GLO1MMP2 | |
| SCHEMBL870765 | 0.92 | TOP2A (0.40) | TOP2ACKS1BSKP2GLO1MMP2 | |
| SCHEMBL597833 | 0.92 | TOP2A (0.40) | TOP2ACKS1BSKP2GLO1MMP2 | |
| SCHEMBL7873518 | 0.91 | TOP2A (0.39) | TOP2ACKS1BSKP2GLO1MMP2 | |
| SCHEMBL27805381 | 0.91 | TOP2A (0.39) | TOP2ACKS1BSKP2GLO1MMP2 | |
| SCHEMBL6037850 | 0.91 | TOP2A (0.39) | TOP2ACKS1BSKP2GLO1MMP2 | |
| Water SCHEMBL8819292 | 0.90 | TOP2A (0.38) | TOP2ACKS1BSKP2GLO1MMP2 | |
| SCHEMBL29026621 | 0.90 | TOP2A (0.38) | TOP2ACKS1BSKP2GLO1MMP2 | |
| SCHEMBL15570898 | 0.87 | TOP2A (0.36) | TOP2ACKS1BSKP2GLO1MMP2 | |
| SCHEMBL8140844 | 0.80 | CKS1B (0.38) | TOP2ACKS1BSKP2GLO1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193746-B2 | Luminescent metal complexes and associated technology | BIOTIUM, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20080145526-A1 | Luminescent Metal Complexes and Associated Technology | BIOTIUM, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145526-A1 | Luminescent Metal Complexes and Associated Technology | CLTA, CLTB, CACYBP | TOP2A 3349/4885CKS1B 3363/4885SKP2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.